Skip to main content
OpenTrials
Completed

NCT Number: NCT03882255

A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State

The primary purpose of this study is to evaluate the effect of the up-titration regimen of ponesimod on heart rate (HR) and other electrocardiogram (ECG) parameters when administrated to healthy adult participants receiving propranolol at steady state.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)

Antwerp, 2060, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Systolic blood pressure (SBP) 90 to 140 millimeters of mercury (mmHg) and diastolic blood pressure (DBP) 50 to 90 mmHg measured on the right arm in supine position after at least 5 minutes rest in the supine position at screening, on Day 1 of the Treatment Period 1, and on Day -2 of Treatment Period 2
  • Body mass index (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m^2 ) (inclusive) at screening and body weight not less than 50.0 kg
  • 12-lead safety electrocardiogram (ECG) without clinically relevant abnormalities at screening, on Day 1 of the Treatment Period 1, and on Day-2 of Treatment Period 2, including:
  • QT interval corrected for heart rate using the Fridericia correction (QTcF) of less than or equal to (=<) 450 millisecond (ms) for male participants and =< 470 ms for female participants
  • Heart rate (HR) 55 to 100 Beats per minute (bpm) (inclusive)
  • QRS interval less than (<) 120 ms
  • PR interval =< 200 ms
  • ECG morphology consistent with healthy cardiac conduction and function
  • Female participant must have a negative highly sensitive serum (beta human chorionic gonadotropin [beta- hCG]) pregnancy test at screening and a negative urine pregnancy test on Day 1 of Treatment Period 1 and Day 2 of Treatment Period 2
  • Negative results from urine drug screen at screening, on Day -1 of Treatment Period 1, and on Day -2 of Treatment Period 2

Exclusion criteria

  • Any cardiac condition or illness (including ECG abnormalities) with a potential to increase the cardiac risk of the participant based on medical history, physical examination, 12-lead safety ECG, or 24-hour Holter ECG at screening, including:
  • 24-hour Holter ECG with clinically relevant abnormalities
  • History or evidence of Atrioventricular (AV) block second degree or higher
  • Any cardiac condition or illness (including ECG abnormalities based on standard 12-lead safety ECG or d- 24-hour Holter ECG) with a potential to increase the cardiac risk of the participant
  • Family history of sick-sinus syndrome
  • Hepatitis A antibody immunoglobulin M (IgM) positive, positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-hepatitis C virus [anti-HCV]) tests, or other clinically active liver disease at screening
  • Known hypersensitivity to any excipients of the ponesimod drug formulation (lactose, microcrystalline cellulose, povidone, sodium lauryl sulfate, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, opadry II brown), or lactose
  • History of significant propranolol side effects or known hypersensitivity to propranolol or to any of its excipients

Treatment and study plan

Ponesimod dose range (2 - 20 mg)

Drug

Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.

Placebo Propranolol

Drug

Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.

Propranolol 80 mg

Drug

Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.

Primary outcomes

  1. Maximum Decrease from Baseline in Mean Hourly Heart Rate (HR) (Emax HR) on Day 5

    Time frame: Baseline and Day 5

    Emax HR is defined as the maximum decrease from baseline in mean hourly HR.

  2. Maximum Decrease from Baseline in Mean Hourly Heart Rate (HR) (Emax HR) on Day 19

    Time frame: Baseline and Day 19

    Emax HR is defined as the maximum decrease from baseline in mean hourly HR.

  3. Minimum of the Mean Hourly HR for each day (HR nadir) on Day 5

    Time frame: Day 5

    HR nadir will be defined as the minimum of the mean hourly HR for each day and will be summarized by descriptive statistics.

  4. Minimum of the Mean Hourly HR for each day (HR nadir) on Day 19

    Time frame: Day 19

    HR nadir will be defined as the minimum of the mean hourly HR for each day and will be summarized by descriptive statistics.

Secondary outcomes

  1. Maximum Decrease from Baseline in Mean Hourly Heart Rate (HR) (Emax HR) on Days 4,16, and 19

    Time frame: Baseline, Days 4, 16, and 19

    Emax HR is defined as the maximum decrease from baseline in mean hourly HR.

  2. Minimum of the Mean Arterial Blood Pressure

    Time frame: Days 4, 5, 16, and 19

    Minimum of the Mean arterial blood pressure (MAP) will be assessed. The MAP will be derived from the systolic blood pressure (SBP) and diastolic blood pressure (DBP) for each participant at the same time point as follows: MAP = 1/3 SBP + 2/3 DBP.

  3. Change from Baseline in Average Heart Rate

    Time frame: Baseline, Days 4, 5, 16, and 19

    Change from baseline in average heart rate on Days 4, 5, 16 and 19 will be assessed in Treatment Period 2.

  4. Change from Baseline in Average PR Interval

    Time frame: Baseline, Days 4, 5, 16, and 19

    Change from baseline in PR interval on Days 4, 5, 16 and 19 will be assessed in Treatment Period 2. PR intervals will be derived from 12-lead safety electrocardiogram (ECG).

  5. Maximum Observed Plasma Analyte Concentration (Cmax) of Ponesimod

    Time frame: Days 5, 9 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    Cmax is defined as maximum observed plasma analyte concentration.

  6. Maximum Observed Plasma Analyte Concentration (Tmax) of Ponesimod

    Time frame: Days 5, 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    Tmax is defined as maximum observed plasma analyte concentration.

  7. Area Under the Plasma Analyte Concentration-Time Curve (AUC [0-24]) of Ponesimod

    Time frame: Day 5 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 Hours postdose)

    (AUC [0-24]) is defined as area under the plasma analyte concentration-time curve (AUC) from time 0 to 24 hours postdose, calculated by linear-linear trapezoidal summation.

  8. Trough Plasma Analyte Concentration (Ctrough) of Ponesimod

    Time frame: Day 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    (Ctrough) is defined as observed analyte concentration just prior to the beginning of a dosing interval.

  9. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    Time frame: Day 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    The AUCtau is the measure of the plasma analyte concentration from time zero to end of dosing interval. AUC during a dosing interval (τ) at steady state, calculated by linear-linear trapezoidal summation.

  10. Maximum Observed Plasma Analyte Concentration (Cmax) of Propranolol and 4 hydroxypropranolol

    Time frame: Days 4, 5, and 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    Cmax is defined as maximum observed plasma analyte concentration.

  11. Maximum Observed Plasma Analyte Concentration (Tmax) of Propranolol and 4 hydroxypropranolol

    Time frame: Days 4, 5, and 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    Tmax is defined as maximum observed plasma analyte concentration.

  12. Trough Plasma Analyte Concentration (Ctrough) of Propranolol and 4 hydroxypropranolol

    Time frame: Days 4, 5, and 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    (Ctrough) is defined as observed analyte concentration just prior to the beginning of a dosing interval.

  13. Area Under the Curve from Time Zero to End of Dosing Interval (AUCtau) of Propranolol and 4 hydroxypropranolol

    Time frame: Days 4, 5, and 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    The AUCtau is the measure of the plasma analyte concentration from time zero to end of dosing interval. AUC during a dosing interval (τ) at steady state, calculated by linear-linear trapezoidal summation.

  14. Total apparent Oral Clearance of Propranolol

    Time frame: Days 4, 5, and 19 (Predose; 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours postdose)

    Total apparent clearance is defined as total apparent oral clearance at steady state, calculated as dose/AUC (tau).

  15. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: Approximately 2.5 months

    An adverse event is any adverse change, that is, any unfavorable and unintended sign, including an abnormal laboratory finding, symptom, or disease, that occurs in a participant during the course of the study, whether or not considered related to the study treatment.

Sponsors and collaborators

Lead sponsor

Janssen Pharmaceutica N.V., Belgium

Industry

Registry information

Official study title

A Randomized, Double-blind, Parallel-group, 2-period, Placebo-controlled, Phase 1 Study to Investigate the Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of the Up-titration Regimen of Ponesimod in Healthy Adult Subjects Receiving Propranolol at Steady State

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 20, 2019
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.